Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.34-13.3% vs -$0.30 | — vs — |
Q2 2026 May 15, 2026 | -$2.53-803.6% vs -$0.28 | — vs — |
Q2 2026 May 14, 2026 | -$2.53-803.6% vs -$0.28 | — vs — |
Q2 2026 Mar 31, 2026 | -$0.62+0.0% vs -$0.62 | — vs — |
Shares of Tempest Therapeutics Inc (NASDAQ:TPST) rose sharply in pre-market trading after the California-based clinical-stage biotechnology company announced an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd.
-Transaction complements Tempest's existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year
$2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrants $2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrants
BRISBANE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer and autoimmune disease, today announced that Matt Angel, Ph.D.
Benchmark TPST against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Tempest Therapeutics, Inc. (TPST)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.04 | $15.8M | -0.16 | — | — | -203.63% | — | |
| $37.29 | $7.7B | -13.46 | — | -7585.86% | -69.59% | — | |
| $8.70 | $362.29M | -2558.82 | 10.37% | 69.76% | — | — | |
| $34.97 | $2.08B | -4.91 | 48.03% | -418.24% | -35.67% | — | |
| $26.87 | $3.38B | -8.17 | -4.26% | -386.32% | -87.98% | — | |
| $60.97 | $2.02B | -6.27 | -43.89% | -287.84% | -37.99% | — |
Tempest Therapeutics, Inc. (TPST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Tempest Therapeutics, Inc. (TPST) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 18, 2026·SEC
Aug 13, 2026·SEC
Aug 13, 2026·SEC
Get notified when TPST posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Tempest Therapeutics, Inc. (TPST) stock FAQ — growth, dividends, profitability & financials explained
Tempest Therapeutics, Inc. (TPST) reported a net loss of $40.5M for fiscal year 2025.
Tempest Therapeutics, Inc. (TPST) has a return on equity (ROE) of -203.6%. Negative ROE indicates the company is unprofitable.
Tempest Therapeutics, Inc. (TPST) had negative free cash flow of $20.7M in fiscal year 2025, likely due to heavy capital investments.
